United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,194,444.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $331.79, for a total transaction of $1,194,444.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $43,132.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Stock Up 0.1 %

UTHR opened at $329.16 on Monday. The stock has a market capitalization of $14.60 billion, a price-to-earnings ratio of 15.56, a price-to-earnings-growth ratio of 1.44 and a beta of 0.55. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $339.56. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The business has a 50-day moving average of $296.57 and a two-hundred day moving average of $253.93.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.86 earnings per share. On average, research analysts expect that United Therapeutics Co. will post 24.87 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. V Square Quantitative Management LLC purchased a new stake in United Therapeutics during the second quarter valued at about $30,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares during the period. Finally, Janiczek Wealth Management LLC increased its position in United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on UTHR. TD Cowen increased their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. JPMorgan Chase & Co. increased their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. UBS Group raised their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $321.55.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.